The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, ...

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, ...

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

TAMPA, FL / / October 22, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ('TuHURA' or the 'Company'), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient ...

If you are facing a recurrence of classic Hodgkin lymphoma, or you have become resistant to your treatment, there is some good news that may help. The FDA approved Keytruda (pembrolizumab), which is ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Adding pembrolizumab to modern, high-quality chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer.